SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
VPHM - Viropharma Inc
An SI Board Since December 1998
Posts SubjectMarks Bans Symbol
2557 72 0 VPHM
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2407Oppenheimers' returns on picks and pans have not performed well: gainerstodThomas Kirwin-11/22/2008
2406Not much of a track record for John Newman's picks and pans. Newman, John EThomas Kirwin-11/22/2008
2405It appears as though the Oppenheimer Analyst has strayed a bit away from his areThomas Kirwin-11/22/2008
2404The patient population of the opt 80 and the tolemaver study were exactly the sarkrw-11/22/2008
2403Proof Source Regarding OPT-80 Failure in Serious CDAD Cases messages.finance.yaThomas Kirwin-11/22/2008
2402Trial was not in mild patients. The only place you'd need a liquid formulatirkrw-11/22/2008
2401The key point was relapse rate, 15% vs 25%, p-value of .005. So if the opt-80 trkrw-11/22/2008
2400Oppenheimer's Smear Campaign Against VPHM That's right folks, OppenheimThomas Kirwin-11/22/2008
2399>>OPT-80 is no Threat.... I know the theory. For now, I am agnostic. ijIRWIN JAMES FRANKEL-11/21/2008
2398OPT-80 is no Threat.... Clinical studies being performed by Optimer PharmaceutiThomas Kirwin-11/21/2008
2397Oppenheimer takes cautious view on ViroPharma Associated Press, 11.21.08, 01:45 IRWIN JAMES FRANKEL111/21/2008
2396Yahoo! Repost - Did some searching to find out why optr did not include the seveThomas Kirwin-11/14/2008
2395Man that biovaluation board is full of posts. It is time for me to circle back kenhott-11/13/2008
2394I'm worried about camvia data risk. A big part of the analyst confusion wrkrw-11/13/2008
2393Some other people apparently didn't like my OT bozo comment to you. I guesskenhott-11/13/2008
2392<I've generally assumed the Optimer drug would become the standard of carkenhott-11/13/2008
2391I think its widely expected that vanco will go generic sooner than later but tharkrw-11/13/2008
2390Your view read remarkably like mine. JonRobohogs-11/13/2008
2389>> I don't think your view of vanco sales is universal. Well some verBiomaven-11/12/2008
2388Bios is getting to be more and more a stock picker segment. Winners are far andkenhott-11/12/2008
2387I heard standard of care may be going to 14 days dosing for cure. The OPTR triakenhott-11/12/2008
2386I've generally assumed the Optimer drug would become the standard of care anBiomaven-11/11/2008
2385V is 4X/day and there's been rumors of very fast responses in the trial, butrkrw-11/11/2008
2384The good news is Romark's Nitazoxanide CD study has been discontinued. And kenhott-11/11/2008
2383DYAX study on societal costs of HAE: biz.yahoo.com FWIWDewDiligence_on_SI-11/10/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News